F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comSupriya Lifescience Ltd, a leading pharmaceutical company in India, is known for its strong portfolio of Active Pharmaceutical Ingredients (APIs) across therapeutic segments such as anti-allergics, vitamins, anesthetics, and more. With a robust global presence, the company has earned recognition as a trusted API manufacturer and exporter. In this article, we’ll explore Supriya Lifescience’s share price target forecasts from 2025 to 2030 along with investment insights.
Let’s analyze the company’s current performance, fundamentals, and future outlook.
| Detail | Value |
|---|---|
| Current Price | ₹666.45 |
| Previous Close | ₹662.35 |
| Day's High | ₹694.00 |
| Day's Low | ₹658.20 |
| 52-Week High | ₹842.00 |
| 52-Week Low | ₹511.40 |
| Market Capitalization | ₹5,544 Cr |
| Beta (Volatility) | 1.92 |
| VWAP | ₹677.16 |
| Face Value | ₹2 |
| All-Time High | ₹842.00 |
| All-Time Low | ₹170.15 |
The stock is currently trading with high volatility, and analysts see both risks and opportunities in its price movement.
Supriya Lifescience, established in 1987, is a key player in the pharmaceutical API sector. The company exports its products to more than 85 countries, with a strong presence in Europe, Latin America, North America, and Asia.
Focused on APIs across anti-allergics, anesthetics, and vitamins
Strong global footprint with approvals from USFDA, EDQM, and WHO GMP
Steady revenue growth from export markets
Innovation-led manufacturing facilities in India
Expanding product pipeline to capture rising global pharma demand
| Investor Type | Holding (%) |
|---|---|
| Promoters | 68.30% |
| Retail & Others | 20.06% |
| Foreign Institutions | 6.78% |
| Other Domestic Institutions | 4.18% |
| Mutual Funds | 0.68% |
The high promoter holding reflects strong promoter confidence, while steady FII participation shows growing global interest.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 650 | 700 |
| 2026 | 720 | 780 |
| 2027 | 800 | 880 |
| 2028 | 870 | 960 |
| 2029 | 950 | 1,050 |
| 2030 | 1,080 | 1,200 |
These targets are based on the company’s financial outlook, EPS growth, pharma sector expansion, and global demand for APIs.
In 2025, the stock may show consolidation due to high volatility (Beta 1.92). However, with strong fundamentals, the price is expected to stabilize.
Why?
Stable revenue from global exports
Rising demand for allergy and vitamin APIs
Strong promoter confidence
Investment Advice: Accumulate during dips; suitable for medium-term investors.
By 2026, earnings growth is expected to improve with expanding global partnerships.
Why?
Better operational efficiency
Entry into new regulated markets
Rising healthcare demand in Asia and Europe
Investment Advice: Hold for long-term compounding; avoid short-term trading.
The company is projected to show upward momentum due to steady export growth.
Why?
Global API demand growth
Expansion of product portfolio
Strong Q3 and Q4 earnings visibility
Investment Advice: Continue holding; good for SIP investments.
By 2028, Supriya may cross the ₹900 level with rising exports.
Why?
Strong international approvals
Improved margins from cost control
Pharma sector boom across emerging markets
Investment Advice: Suitable for long-term investors targeting steady CAGR growth.
A key year where the stock may breach the ₹1,000 mark.
Why?
Strong financial performance
Higher dividend payouts possible
Consistent global demand
Investment Advice: A strong pick for long-term wealth creation.
By 2030, Supriya Lifescience may achieve strong global leadership in APIs.
Why?
Strong promoter backing
High institutional interest
Continued global expansion and robust EPS growth
Investment Advice: Excellent for long-term portfolios; potential multibagger opportunity.
Yes. With its strong promoter holding, global export presence, and diversified product portfolio, Supriya Lifescience is a promising long-term investment.
High promoter confidence (68.30% holding)
Expanding global market reach
Stable financial growth and earnings visibility
API demand to rise globally over the next decade
High volatility (Beta 1.92) may lead to sharp price movements
Dependency on export approvals and global regulations
Currency fluctuations impacting export revenues
Supriya Lifescience Ltd is well-positioned for long-term growth in the pharmaceutical API sector. With strong fundamentals and global expansion, the share price target of ₹1,200 by 2030 looks achievable. Investors with a long-term horizon can consider Supriya Lifescience as part of their portfolio for stable growth and sectoral diversification.
What is the share price target of Supriya Lifescience for 2025?
The 2025 target is ₹650 – ₹700, depending on market performance.
Will Supriya Lifescience cross ₹1,000 by 2029?
Yes, projections suggest the stock may cross ₹1,000 by 2029.
Is Supriya Lifescience a good buy now?
It can be a good buy for long-term investors due to its strong fundamentals and export growth.
What is the 2030 target for Supriya Lifescience?
By 2030, the stock may trade between ₹1,080 – ₹1,200.
What is the promoter holding in Supriya Lifescience?
Promoters currently hold 68.30%, reflecting strong confidence in the company.
Is Supriya Lifescience a risky stock?
The stock has high volatility (Beta 1.92), but strong fundamentals reduce long-term risks.
What is the all-time high of Supriya Lifescience?
The all-time high is ₹842.00.
What is the all-time low of Supriya Lifescience?
The all-time low is ₹170.15.
Does Supriya Lifescience have global approvals?
Yes, the company has approvals from USFDA, EDQM, and WHO GMP.
Should I hold Supriya Lifescience for the next 5 years?
Yes, for long-term investors, holding Supriya Lifescience could provide strong returns by 2030.
Disclaimer: This article is for educational purposes only. Please consult a financial advisor before investing.
Register & Login